Resolution Therapeutics Advances Engineered Macrophage Platform as Long-Term MATCH Data Strengthen Rationale

New updates have been reported about Resolution Therapeutics.

Resolution Therapeutics is sharpening its strategic position in liver disease with new long-term clinical evidence supporting its Regenerative Macrophage Therapy (RMT) platform, as it progresses its lead engineered candidate RTX001 through the Phase I/II EMERALD trial in end-stage liver disease. The company highlighted four-year follow-up data from the University of Edinburgh’s MATCH study, published in Cell Stem Cell, which showed that first-generation, non-engineered RMT achieved a favourable safety profile and materially improved transplant-free survival versus standard care.

While MATCH evaluated patients’ own unmodified macrophages, the findings are being used by Resolution to reinforce the scientific and clinical rationale for its more potent, engineered RMT approach, in which macrophages are enhanced with IL-10 and MMP9 to boost anti-inflammatory and anti-fibrotic activity for more severe cirrhotic populations. In MATCH, 70% of treated patients remained alive without liver transplant at four years, compared with 40% under standard care, a result that underpins Resolution’s belief that RTX001 can address a significant unmet need in patients who have already experienced decompensation events, such as gastrointestinal bleeding or hepatic encephalopathy.

The EMERALD study, conducted across leading liver centres in the U.K. and Spain, is expected to deliver interim data in the second half of this year, a key value inflection point for Resolution and its investors as the company seeks to validate safety, biological activity, and potential signals of efficacy in end-stage liver disease. Chief Medical Officer Dr. Clifford Brass said the MATCH data provide important long-term human evidence that macrophage-based therapies can modify the course of hepatic inflammation and fibrosis, supporting the strategic bet on engineered RMT as a first-in-class modality.

Beyond RTX001, Resolution is using its proprietary macrophage engineering platform to build a broader pipeline in inflammatory and fibrotic conditions, including preclinical programmes in graft-versus-host disease and lung fibrosis that could diversify future revenue streams if successful. Founded as a spinout from Professor Stuart Forbes’s lab at the University of Edinburgh and operating from Edinburgh and London, the company is positioning itself as a leader in macrophage therapeutics, with upcoming EMERALD data likely to influence partnering options, capital requirements, and the pace of its expansion into additional indications.